ImageneBio (IMA) Non-Current Assets (2020 - 2025)
ImageneBio (IMA) posted Non-Current Assets of $12.7 million for Q4 2025, down 4.93% sequentially from $13.3 million in Q3 2025, and up 267.34% YoY from $3.5 million in Q4 2024.
ImageneBio (IMA) Non-Current Assets (2020 - 2025) Analysis & Trends
ImageneBio has reported Non-Current Assets for 6 years, with the latest figure at $12.7 million in Q4 2025.
- Quarterly Non-Current Assets rose 267.34% year-over-year to $12.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.0 million (up 118.4% YoY) and the FY2025 annual result came in at $12.7 million, up 267.34% from the prior year.
- Non-Current Assets slipped to $12.7 million in Q4 2025 per IMA's latest filing, from $13.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $27.2 million in Q2 2025 and troughed at $3.5 million in Q4 2024.
- A 5-year average of $11.9 million and a median of $11.7 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets soared 366.65% in 2021, then sank 74.28% in 2024.
- Over 5 years, Non-Current Assets stood at $11.4 million in 2021, then climbed by 7.8% to $12.2 million in 2022, then climbed by 9.64% to $13.4 million in 2023, then sank by 74.28% to $3.5 million in 2024, then surged by 267.34% to $12.7 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $12.7 million, $13.3 million, and $27.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | 12.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.69 Mn |
| Sep 30, 2025 | 13.35 Mn |
| Jun 30, 2025 | 27.15 Mn |
| Mar 31, 2025 | 13.84 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 7.46 Mn |
| Jun 30, 2024 | 8.16 Mn |
| Mar 31, 2024 | 11.62 Mn |
| Dec 31, 2023 | 13.43 Mn |
| Sep 30, 2023 | 14.70 Mn |
| Jun 30, 2023 | 11.12 Mn |
| Mar 31, 2023 | 11.22 Mn |
| Dec 31, 2022 | 12.25 Mn |
| Sep 30, 2022 | 12.49 Mn |
| Jun 30, 2022 | 12.04 Mn |
| Mar 31, 2022 | 11.70 Mn |
| Dec 31, 2021 | 11.36 Mn |
| Sep 30, 2021 | 9.84 Mn |
| Jun 30, 2021 | 10.12 Mn |
| Mar 31, 2021 | 10.43 Mn |